NEW YORK, March 29, 2017 /PRNewswire/ --
On Tuesday, March 28, 2017, the NASDAQ Composite,
Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc.'s stock finished Tuesday's session 0.75% higher at $121.19 with a total volume of 885,872 shares traded. Over the last one month and the previous three months, Zimmer Biomet's shares have advanced 3.62% and 18.72%, respectively. Furthermore, the stock has gained 15.22% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 2.97% and 2.87%, respectively. Share of Zimmer Biomet, which together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, Middle East, Africa, and Asia/Pacific, are trading at a PE ratio of 80.21. The stock has a Relative Strength Index (RSI) of 60.02. See our free and comprehensive research report on ZBH at:
Pleasanton, California headquartered ZELTIQ Aesthetics Inc.'s stock edged 0.11% higher, to close the day at $55.84. The stock recorded a trading volume of 572,404 shares. ZELTIQ Aesthetics' shares have gained 0.65% in the last one month, 28.04% in the previous three months, and 114.27% in the past one year. The Company's shares are trading 9.77% and 37.50% above its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which engages in developing and commercializing non-invasive products for the selective reduction of fat, have an RSI of 76.34. ZLTQ free research report PDF is just a click away at:
On Tuesday, shares in Kalamazoo, Michigan headquartered Stryker Corp. ended the session 0.16% higher at $132.70 with a total volume of 749,309 shares traded. Stryker's shares have advanced 3.20% in the last one month and 10.28% in the previous three months. Furthermore, the stock has gained 25.43% in the past one year. Shares of the Company, which together with its subsidiaries, operates as a medical technology company, are trading at a PE ratio of 30.50. The stock is trading 4.65% above its 50-day moving average and 12.17% above its 200-day moving average. Moreover, the Company's shares have an RSI of 65.73.
On March 03rd, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $129 a share to $135 a share. Sign up for your complimentary report on SYK at:
On Tuesday, shares in Audubon, Pennsylvania headquartered Globus Medical Inc. recorded a trading volume of 844,657 shares, which was higher than their three months average volume of 847,700 shares. The stock ended the day 0.94% lower at $29.60. Shares of the Company, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, are trading at a PE ratio of 27.36. Globus Medical's stock has advanced 3.46% in the last one month and 20.57% in the previous three months. Furthermore, the stock has gained 26.12% in the past one year. The Company's shares are trading above its 50-day and 200-day moving averages by 7.94% and 21.62%, respectively. Furthermore, Globus Medical's shares have an RSI of 69.32. Register for free on Stock-Callers.com and download the latest research report on GMED at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All